AmerisourceBergen Corp

Most Recent

  • should i buy or sell amerisource bergen stock
    Investments & Deals

    AmerisourceBergen and Walgreens Sign 'Deal of a Lifetime'

    By Rachel Curry
  • uploads///dECLINES
    Company & Industry Overviews

    S&P 500’s Top Losses: Why Biogen Declined

    Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.

    By Val Kensington
  • uploads///GILD
    Company & Industry Overviews

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.

    By Kenneth Smith
  • uploads///us pharmacies
    Company & Industry Overviews

    How Pharmacies and Drugstores Are Defending against Amazon

    Amazon’s (AMZN) purchase of PillPack is expected to pose a threat to existing players in the pharmaceutical space.

    By Anne Shields
  • uploads///trump tower _
    Consumer

    Drugstore Stocks Tumble ahead of Trump’s New Drug Policy

    The stocks of top drugstore chains CVS Health (CVS) and Walgreens Boots Alliance (WBA) were down yesterday amid ongoing tensions regarding a policy change in US drug pricing.

    By Sonya Bells
  • uploads///LHC
    Company & Industry Overviews

    What’s LHC Group’s Business Strategy?

    In 2018, LHC Group is expected to report revenue of $1.2 billion. What about its peers?

    By Kenneth Smith
  • uploads///DEPO
    Company & Industry Overviews

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow.

    By Kenneth Smith
  • uploads///doctors office checkup medical
    Company & Industry Overviews

    Analysts’ Ratings for AmerisourceBergen in March 2018

    Four analysts gave AmerisourceBergen stock a “strong buy” rating, seven analysts gave it a “buy” rating, and seven analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///ABC revenue
    Company & Industry Overviews

    AmerisourceBergen’s Financial Performance in 1Q18

    In 1Q18, AmerisourceBergen (ABC) generated revenues of $40.4 billion—compared to $38.1 billion in 1Q17.

    By Kenneth Smith
  • uploads///ABC
    Company & Industry Overviews

    Analyzing AmerisourceBergen’s Recent Acquisitions

    In December 2017, AmerisourceBergen (ABC) acquired Northeast Supply Company, or NEVSCO, for a consideration of $70 million.

    By Kenneth Smith
  • uploads///ABC segments
    Company & Industry Overviews

    AmerisourceBergen’s Business Segments

    AmerisourceBergen’s (ABC) operations are organized based on the products and services it provides to customers.

    By Kenneth Smith
  • uploads///
    Consumer

    How the Drug Store Industry Is Changing

    The top three drugstore chains in the US are in the process of forming new associations through mergers and acquisitions to create a more diversified portfolio and protect themselves from the growing online threat.

    By Sonya Bells
  • uploads///Graph
    Company & Industry Overviews

    Patient Recovery Acquisition May Boost Cardinal Health’s Revenues

    On July 30, 2017, Cardinal Health (CAH) completed the acquisition of Medtronic’s patient recovery business for an all-cash consideration worth $6.1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Robust Growth Expected for Cardinal Health’s Specialty Solutions

    Cardinal Health’s (CAH) Specialty Solutions segment provides two types of services: upstream to pharmaceutical and biopharmaceutical manufacturers and downstream to healthcare providers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cardinal Health: Stable Net Profit Margins in Fiscal 2018?

    Wall Street analysts have projected Cardinal Health’s fiscal 2018 net profit margins to be 1.0%, which will be similar to what the company reported in fiscal 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cardinal Health Expected to Report Modest Revenue Growth

    For fiscal 2018, Cardinal Health (CAH) has projected mid-single-digit revenue growth on a YoY basis, partially driven by the company’s high customer retention rates.

    By Margaret Patrick
  • uploads///
    Miscellaneous

    Wall Street Sees a 22% Upside in Walgreens

    Walgreens is covered by 25 Wall Street analysts. The company has received a rating of 2 on a scale of 1 (strong buy) to 5 (sell). It has 72% “buy” and 28% “hold” recommendations and no “sell” recommendations.

    By Sonya Bells
  • uploads///part
    Real Insights

    Primary Detractor in the U.S. Moat Index’s Performance in April

    For April, the top three detractors in MOAT were healthcare companies like AmerisourceBergen (ABC), Express Scripts (ESRX), and McKesson (MCK).

    By VanEck
  • uploads///
    Earnings Report

    Walgreens’s Currency Headwinds for Its International Businesses

    In the last couple of quarters, Walgreens Boots Alliance’s (WBA) fiscal 1Q17 top line was negatively affected by currency headwinds, falling 1.8% YoY.

    By Sonya Bells
  • Materials

    Why Has the JPMorgan Large-Cap Growth Fund Done so Poorly in 2016?

    The JPMorgan Large-Cap Growth Fund Class A (OLGAX) has dived by 3.9% YTD in 2016. This decline makes it the worst performer among our 12 funds.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Have XLV’s Large-Caps Performed?

    XLV has 49 large-cap stocks in its holdings, with a combined market cap of more than $10 billion. Among them, 47 stocks fell on March 15, 2016.

    By Peter Neil
  • uploads///Stock Price Chart
    Company & Industry Overviews

    An Analysis of Walgreens Boots Alliance’s Stock Returns

    Walgreen Boots Alliance’s (WBA) common stock trades on the NASDAQ under the symbol “WBA.”

    By Sonya Bells
  • uploads///
    Company & Industry Overviews

    A Look at Walgreens Boots’ Pharmaceutical Wholesale Division

    Walgreens Boots Alliance’s (WBA) Pharmaceutical Wholesale division consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses.

    By Sonya Bells
  • uploads///
    Company & Industry Overviews

    A Look at Walgreens Boots Alliance’s Retail Pharmacy USA Division

    The Retail Pharmacy USA division is Walgreens Boots Alliance’s (WBA) largest revenue generator.

    By Sonya Bells
  • uploads///
    Company & Industry Overviews

    Walgreens Boots Alliance: Merger of Walgreens and Alliance Boots

    Walgreens became a wholly owned subsidiary of Walgreens Boots Alliance after a merger.

    By Sonya Bells
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.